What Is Semax Peptide? A Neuropeptide Research Guide

What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It's an analogue of the ACTH(4-10) fragment — that is, amino acids 4 through 10 of adrenocorticotrophic hormone — with a proline-glycine-proline extension at the C-terminus that improves metabolic stability by protecting against carboxypeptidase degradation. The molecular weight is 813.93 Da.

Developed at the Institute of Molecular Genetics, Russian Academy of Sciences, in the 1980s by Ashmarin and colleagues, Semax has been approved in Russia as a prescription medication (marketed as a 0.1% nasal spray under the trade name Semax) since the early 2000s. It's prescribed for conditions including stroke recovery, cognitive enhancement, and optic nerve disorders. It's not approved or licensed in the UK or EU — its regulatory status here is as a research chemical, not a medicine.

What makes Semax unusual among synthetic peptides is the depth of research behind it. There are hundreds of published studies, but a significant proportion are in Russian-language journals that aren't indexed on PubMed, which creates an accessibility gap for English-speaking researchers. The peptide deserves more attention from Western research groups than it currently receives — the mechanistic data that is available in English is genuinely compelling.

The design philosophy behind Semax is elegant: take the minimum active fragment of ACTH responsible for its nootropic and neuroprotective effects (residues 4-10), remove the hormonal activity associated with the full ACTH molecule (which acts on adrenal cortex melanocortin receptors), and stabilise the fragment against enzymatic degradation. The result is a peptide with neurotrophic activity but without the endocrine side effects of ACTH administration.

How does Semax work?

Semax's mechanism of action is multifaceted, reflecting its origins as an ACTH fragment. ACTH normally acts on melanocortin receptors, but Semax's activity extends well beyond this single pathway — it's more accurately described as a pleiotropic neuropeptide.

BDNF and neurotrophin upregulation

The most consistently reported effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF). Dolotov et al. (2006) demonstrated that Semax increases BDNF mRNA expression in the rat hippocampus and cortex within hours of administration (DOI: 10.1016/j.neulet.2005.12.003). BDNF is a critical neurotrophin for synaptic plasticity, neuronal survival, and long-term memory formation — it's essentially the molecular substrate of learning.

Semax also influences nerve growth factor (NGF) and neurotrophin-3 (NT-3) expression, suggesting broad neurotrophic activity rather than a narrow BDNF-specific effect. The upregulation of multiple neurotrophins simultaneously is unusual and potentially significant — most pharmacological interventions affect one neurotrophin pathway preferentially.

The time course matters: BDNF mRNA increases within 30 minutes of intranasal administration, peaks at 3–6 hours, and returns to baseline by 24 hours. This suggests that repeated dosing maintains elevated neurotrophin levels, while single doses produce a transient pulse — a distinction that affects experimental design.

Melanocortin receptor activity

As an ACTH analogue, Semax interacts with melanocortin receptors — particularly MC3R and MC4R, which are expressed throughout the central nervous system. MC4R activation influences learning, memory, anxiety, feeding behaviour, and pain perception. However, Semax's affinity for melanocortin receptors is lower than its parent fragment ACTH(4-10), and the neurotrophic effects may be the more therapeutically relevant pathway.

Importantly, Semax does not significantly activate MC2R — the adrenal melanocortin receptor responsible for cortisol release. This is a deliberate design feature: the nootropic effects of ACTH fragments are preserved while the endocrine effects are minimised. Researchers do not see cortisol elevations following Semax administration, which distinguishes it from ACTH itself.

Anti-inflammatory and neuroprotective effects

Semax reduces the expression of pro-inflammatory genes following cerebral ischaemia. In a transcriptomic study by Dergunova et al. (2018), Semax treatment after middle cerebral artery occlusion in rats modulated the expression of over 100 genes related to the inflammatory response, with net suppression of pro-inflammatory pathways (DOI: 10.1186/s12864-018-5019-3). The affected genes included cytokines (IL-1beta, IL-6), chemokines (CXCL1, CXCL2), and adhesion molecules involved in leucocyte recruitment to the ischaemic brain.

This anti-inflammatory profile, combined with BDNF upregulation, creates a dual neuroprotective mechanism: reducing ongoing secondary damage from neuroinflammation while simultaneously promoting repair, plasticity, and neuronal survival. The combination is theoretically powerful — most neuroprotective strategies target either inflammation or neurotrophic support, not both.

Dopaminergic and serotonergic modulation

Semax influences monoamine turnover in the brain. Studies report increased dopamine and serotonin metabolite levels in the striatum and cortex, suggesting enhanced monoaminergic transmission. Specifically, DOPAC (the primary dopamine metabolite) and 5-HIAA (the primary serotonin metabolite) levels increase, indicating greater transmitter release and turnover rather than simply increased synthesis. This may underlie some of the cognitive and mood-related effects reported in animal studies.

Epigenetic mechanisms

Emerging research suggests Semax may influence gene expression through epigenetic modifications — particularly histone acetylation in hippocampal neurons. This is a frontier area and the data is preliminary, but if confirmed, it would suggest that Semax's effects on neuroplasticity may persist beyond the period of direct neurotrophin elevation.

What does the preclinical and clinical evidence show?

Cognitive enhancement

In rodent models, Semax improves performance on spatial learning tasks (Morris water maze), passive avoidance conditioning, and novel object recognition. The effects are dose-dependent and appear mediated through BDNF-dependent mechanisms — blocking BDNF signalling with TrkB antagonists attenuates Semax's cognitive effects. The cognitive improvements are seen in both healthy animals and those with experimentally induced cognitive deficits, though the effect size is larger in the impaired models.

In Russian clinical practice, Semax is used for cognitive support, though the clinical trial data available in English is limited. The trials that are accessible generally involve small sample sizes and lack the rigorous designs (double-blind, placebo-controlled, multi-centre) expected by Western regulatory standards. This doesn't mean the findings are wrong — it means they haven't been validated to the standards required for approval by the MHRA or EMA.

Stroke and cerebral ischaemia

This is the area with the most clinical evidence. Semax has been studied as an adjunct treatment for ischaemic stroke in several Russian clinical trials. Gusev and Skvortsova (2003) reported improved neurological outcomes when Semax was administered intranasally within the first 12 hours post-stroke. The proposed mechanism involves both neuroprotection (reducing apoptosis in the penumbra — the at-risk tissue surrounding the core infarct) and neuroplasticity (BDNF-mediated rewiring of surviving circuits).

The stroke data is particularly interesting because it represents one of the few areas where Semax has been tested in humans, albeit in trials that wouldn't satisfy FDA or MHRA standards. The biological plausibility is strong: the penumbra is ischaemic but salvageable tissue, and both anti-inflammatory and neurotrophic interventions have theoretical roles in preserving it.

Optic nerve disorders

Semax is prescribed in Russia for optic nerve disease, including glaucoma and optic atrophy. The rationale is neurotrophic support for retinal ganglion cells, which are BDNF-dependent and die progressively in glaucoma. Published data shows preservation of visual function in animal models, though controlled human trials meeting Western standards are limited. The eye represents an attractive target for peptide therapy because intranasal administration may deliver meaningful concentrations to the optic nerve via perineural pathways.

Anxiety and stress response

Animal studies suggest anxiolytic effects at certain doses, possibly mediated through melanocortin and serotonergic pathways. Semax appears to modulate the HPA axis response to acute stress without the suppressive effects of exogenous glucocorticoids — a potentially useful property for stress research models.

How is Semax used in research?

Semax is typically administered intranasally in both animal and clinical studies, which is unusual for a research peptide and reflects its Russian pharmaceutical heritage. The nasal route provides relatively rapid CNS delivery, bypassing the blood-brain barrier to some extent through olfactory and trigeminal nerve pathways.

In vivo rodent protocols: Intranasal administration at doses of 50–600 microg/kg is standard. The peptide is dissolved in saline and applied dropwise to the nasal mucosa using a micropipette. For mice, typical volumes are 1–2 microL per nostril; for rats, 5–10 microL per nostril. The animal should be lightly restrained and the head positioned to prevent immediate drainage.

In vitro work: Semax is used at concentrations of 0.1–100 microM in neuronal cell culture and brain slice preparations. It's soluble in water and stable in physiological buffers at neutral pH. Primary hippocampal and cortical neuron cultures are the most commonly used in vitro models.

Storage: Lyophilised Semax should be stored at -20 degrees C. Once reconstituted, store at 2–8 degrees C and use within 14 days. The methionine residue at position 1 makes Semax susceptible to oxidation — protect reconstituted solutions from atmospheric oxygen and light exposure. See Read more for full handling recommendations.

For product specifications and analytical data, visit Read more. All batches come with third-party Read more verification.

What are the gaps in Semax research?

1. Language barrier: A substantial portion of the evidence base is in Russian. Systematic review and meta-analysis are difficult when a large fraction of the primary literature is inaccessible to most Western researchers.

2. Clinical trial quality: The available human studies generally don't meet CONSORT guidelines, pre-registration standards, or the blinding and randomisation requirements expected for regulatory approval.

3. Mechanism granularity: While downstream effects (BDNF upregulation, monoamine modulation) are well characterised, the precise initial binding events and proximal signalling cascades need further elucidation.

4. Long-term safety data: Chronic administration data is scarce, particularly outside Russian sources. Potential long-term effects of sustained neurotrophin elevation are unknown.

5. Species translation: Most preclinical data is in rodents. Primate studies are almost non-existent, limiting translational confidence.

These gaps represent real opportunities for UK and European research groups. The mechanistic foundation is strong enough to justify further investigation, but the work needs to be done to Western methodological standards.

How does Semax compare to other neuropeptides?

Semax sits in a family alongside Selank (another Russian-developed heptapeptide, derived from tuftsin, with anxiolytic and immunomodulatory properties), NA-Semax (an acetylated analogue with improved nasal absorption and potentially enhanced CNS penetration), and Semax-amidate (C-terminal amidated form with different metabolic stability). Each has slightly different pharmacokinetic properties, but Semax remains the most extensively studied.

Compared to other nootropic peptides, Semax's distinguishing feature is its neurotrophin-upregulating capacity. Most nootropic compounds act on neurotransmitter systems directly — racetams on cholinergic function, modafinil on dopaminergic/histaminergic systems. Semax also does this, but its BDNF effects suggest a role in structural and functional neuroplasticity that goes beyond simple neurotransmitter modulation. It's not just making existing circuits work faster — it's potentially enabling the formation and strengthening of new connections.

References

1. Dolotov, O.V. et al. (2006). "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." *Neuroscience Letters*, 399(1-2), 1–6. DOI: 10.1016/j.neulet.2005.12.003

2. Dergunova, L.V. et al. (2018). "Genome-wide transcriptome analysis using RNA-Seq reveals a large number of differentially expressed genes in a transient MCAO rat model." *BMC Genomics*, 19, 655. DOI: 10.1186/s12864-018-5019-3

3. Ashmarin, I.P. et al. (2005). "Peptide nootropics and neurotrophins." *Biochemistry (Moscow)*, 70(3), 239–244. DOI: 10.1007/s10541-005-0114-x

---

Research Use Only Disclaimer

All peptides sold by Premio Peptides are strictly for laboratory and research purposes. They are not intended for human consumption, therapeutic use, or as food supplements. Researchers are responsible for ensuring compliance with all applicable regulations in their jurisdiction. Premio Peptides does not condone or encourage the use of these products outside a controlled research environment.

*Published by the Premio Peptides research team. Peer-reviewed sources cited throughout.*